Introduction
Development of imatinib mesylate has considerably modified the therapeutic algorithms for patients with CML. Owing to its effectiveness and absence of major toxicities, imatinib has become the front-line treatment in most cases. 1 Moreover, imatinib has progressively displaced haematopoietic cell transplantation (HCT), the only curative option for this disease, even in patients having an HLA-identical sibling, due to the high morbidity and mortality of this approach. 2, 3 However, in the last decade, several advances in the management of patients undergoing HCT have notably reduced the morbidity and mortality of both related and unrelated donor HCT (UD-HCT), procedures that at the present time offer similar results. 4 Additionally, the increasing number of volunteer donors in the international registries has facilitated the location of suitable donors 5 and today around 40% of patients can have a donor with the most commonly used match criteria (HLA-A, -B, -C and -DRB1 identity at allele level). [4] [5] [6] [7] For all these reasons, at the present time, some authors believe that HCT and UD-HCT should be considered not only for patients unresponsive or intolerant to imatinib but also for young patients with expectable low-risk transplantation. The aim of the present study was to analyse if the described improvement in transplant outcome occurred in our media, comparing results of the last decade with those observed in our previous national analysis, 8 and to identify the subgroups of patients in which UD-HCTs offer the best results.
Patients and methods

Inclusion criteria
We retrospectively analysed the UD-HCT performed in Spain for patients older than 15 years with CML in the first chronic phase (CML-1CP) receiving a peripheral blood or bone marrow transplantation. Additionally, all donorrecipient pairs should have been typed, as a minimum, for HLA-A and -B loci by low-resolution (LR) techniquesserological or DNA-based -, and for DRB1 locus using high-resolution (HR) techniques.
Patient population
Between November 1994 and January 2003, 92 consecutive patients fulfilling the inclusion criteria underwent UD-HCT in the ten Spanish Transplant Centres participating in the study. These centres performed 89% of the UD-HCTs for CML in Spain during the aforementioned period (data provided by the Spanish Bone Marrow Donor Registry -REDMO). Some UD-HCTs performed before February 1998 were also included in our previous report. 8 In all, 73% of transplants were performed at three institutions (Hospital Clı´nic (n ¼ 31), Hospital La Princesa (n ¼ 20), Hospital Reina Sofı´a (n ¼ 16)). Table 1 shows the most relevant aspects of the included patients. The patients' median age was 32 years (range, 15-49 years). The median interval from CML diagnosis to UD-HCT was 23 months (range, 3-337 months). Sixteen (17%) were performed during the first year after diagnosis and 33 (36%) during the second year. A total of 72 patients (67%) had received interferon, four interferon and imatinib and three imatinib before UD-HCT. The donors' median age was 36 years (range, 22-56 years). Table 1 shows the serological CMV status and sexmatch relationship between donor and recipient.
Transplantation procedures
Preparative regimens and GvHD prophylaxis varied according to the transplant centre policies and over time, but most of them received cyclophosphamide (Cy) and total body irradiation (TBI) (89%) and cyclosporine (CsA) and short methotrexate (MTX) (83%), respectively (Table 1 ). In 37 (40%) out of 64 cases receiving only CsA þ MTX, CsA was administered from day À1, and in 27 (29%) from day À7. T-cell depletion (TCD) was performed in 11 (12%) cases by means of monoclonal antibodies (n ¼ 7), counterflow elutriation (n ¼ 3) and positive selection (n ¼ 1). Five patients received tacrolimus associated with short MTX.
HLA typing and donor-recipient matching Two levels of typing were considered: HR, when the complete allele was determined by DNA methods, and LR, when only the first 2 digits of the allele were determined by serological or DNA methods. Donors and recipient pairs considered were those who matched at allele level (or HR match) for a given locus when they showed the same 4 digits, and those who matched at antigen level (or LR match) when the two digits determined were identical.
As required by the inclusion criteria, all pairs had DRB1 locus typed at allele level; 72 (78%) of them also had the DQB1 locus analysed at allele level. In 25 (27%) of the donor-recipient pairs, A, B and C loci were typed by means of HR techniques. In the remaining cases, only A and B loci were evaluated: in 62 pairs (67%) by LR and in five by HR techniques. DRB3/4/5 loci, despite being typed in some cases, were not included in the present analysis.
The degree of donor-recipient pair matching is shown in Table 2 . In all, 12 pairs (13%) matched for A, B, C, DRB1 and DQB1 loci at allele level (10/10 HR match). Four pairs (4%) matched at allele level for the eight loci tested (A, B, DRB1 and C or DQB1) (8/8 HR match). A total of 40 pairs (43%) matched at the eight or ten loci tested, but A, B7C loci were tested by LR methods and DRB1 and DQB1 by HR techniques (8/8 or 10/10 LR match). In all, 17 (18%) pairs matched at the six loci analysed (A, B by LR and DRB1 by HR -6/6 LR match). Nine pairs (10%) with A, B, C, DRB1 and DRQ1 loci typed at allele level had one antigen or allele mismatch (9/10 HR match). In all, 10 pairs (11%) with class I loci tested by LR techniques showed one or more antigen mismatches (p5/6 LR match). In summary, 73 pairs (79%) matched for DRB17DQB1 loci at allele level and for A, B and C loci at antigen or allele 
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Engraftment, GvHD and relapse
Neutrophil and platelet engraftment were considered to have occurred on the first of three consecutive days with an absolute neutrophil count X500/ml or self-sustained platelets X20 000/ml, respectively. The analysis of graft failure was limited to patients who survived at least 28 days, and was defined as the absence of an absolute neutrophil count X500/ml for at least 3 consecutive days. A decrease in absolute neutrophil count to o200/ml for at least 3 consecutive days after initial engraftment was considered as secondary graft failure. Acute GvHD was graded as 0-IV 9 and chronic GvHD was defined as none, limited and extensive 10 in patients surviving more than 100 days without relapse. Relapse was defined by either morphologic recurrence of leukaemia or by sustained evidence of the Philadelphia chromosome. Recurrence of leukaemia due to the use of an autologous haematopoietic cell back-up infused to treat a graft failure was not considered a true relapse and these patients were censored for relapse and disease-free survival (DFS) analysis at the moment of back-up infusion.
Statistical analysis
All evaluations were based on data available on July 1, 2003. Descriptive statistics were calculated and reported. The estimated probability (795% confidence interval (CI)) of acute GvHD, survival (SRV) and DFS were evaluated by the Kaplan-Meier method. 11 Kaplan-Meier curves were compared by the log-rank test to assess the impact of various pretransplant variables (see Table 3 ) on SRV and DFS. Additionally, we calculated the estimated probability of cumulative incidence (795% CI) of relapse, chronic GvHD and TRM, 12 in which death without relapse, relapse or death without chronic GvHD, or death due to relapse, respectively, were considered as competing events. A Cox proportional-hazard model 13 was used for quantifying the relationship between SRV and the above-mentioned pretransplant variables; all variables with a P-value o0.2 in the univariate analysis were included in this model. P-values of 0.05 or less were considered to indicate statistical significance. As our series only included patients in 1CP receiving an UD-HCT, we applied the risk assessment score described by Gratwohl et al. 14 using the remaining three variables with the same original score (patient age (o20 y ¼ 0; 20-40 ¼ 1, 440 y ¼ 2), sex mismatch (female to male ¼ 1 vs others combinations ¼ 0), and interval diagnosis HCT (less than 1 year ¼ 0 vs others ¼ 1)). Statistical analyses were performed using SPSS 15.1, Statistica 6.1. and NCSS software. Table 4 shows the incidence of the main post-transplantation events among patients at risk.
Results
Engraftment
Three (3%) patients died during the first 21 days after HCT (two cases due to infections, one due to VOD) and 89 were considered for engraftment. Primary graft failure occurred in four patients (4%) and only one of them in chronic phase is alive after receiving an autologous back-up. Seven patients developed a secondary graft failure on days þ 30, þ 40, þ 40, þ 43, þ 44, þ 50, þ 100, respectively. Three died due to infections, three had a second haematopoietic cell infusion from the same donor and two of them recovered, and the last patient is alive in chronic phase, after receiving an autologous back-up. The median time to neutrophil recovery (4500/ml) was 19 days (range, 10-32). In all, 13 patients with neutrophil engraftment never reached self-sustained platelet counts exceeding 20 000/ml. The median time to platelet recovery for the remaining patients was 22 days (range, 9-360 days).
Graft-versus-host disease
In all, 69 patients (81% of patients at risk) developed acute GvHD (grade I: 16; II: 30; III: 10; IV: 13). The actuarial probability of acute GvHD grade II-IV and grade III-IV were 60% (95% CI: 49-71%) and 25% (95% CI: 16-34%), respectively. In all, 29 (53%) out of 66 patients at risk developed chronic GvHD (limited: 12; extensive: 17). The cumulative incidence of extensive chronic GvHD was 36% (95% CI: 27-49%).
Relapse
Two patients who received an autologous back-up are alive, with CML in the chronic phase. Three patients relapsed on days þ 70, þ 300 and þ 780, respectively, and two of them died due to the progression of the disease. The cumulative incidence of relapse in this series was 5% (95% CI: 2-18%).
Cause of death A total of 43 (47%) patients died after UD-HCT. Their median follow-up after transplantation was three months Impact of donor selection in unrelated HCT for CML E Carreras et al (range, 0.5-27 months). The main causes of death are shown in Table 4 . Infection was the major cause of death in 20 patients (22%), with GvHD being a contributing cause in 12 (13%). The cumulative incidence of TRM in this series was 48% (95% CI: 38-60%).
Survival and disease-free survival
The actuarial probability of SRV and DFS at 4 years for the entire group was 50% (95% CI: 39-61%) and 46% (95% CI: 35-57%), respectively. The median follow-up of surviving patients was 31 months (range, 6-101 months). The Karnofsky performance status among patients with more than 6 months of follow-up was: 100% in 40 patients (82%), 90% in three and 80% or less in six (12%). Univariate analysis (Table 3 and Figure 1) showed that pretransplant factors associated with a better survival were: patient age lower than 25 years (P ¼ 0.035); donor age p36 years (P ¼ 0.012); use of CsA since day À7 as GvHD prophylaxis (P ¼ 0.001); and degree of matching 8/8, 9/10 or 10/10 by HR techniques (P ¼ 0.003). When analysed separately, patients with 10/10 and those with 8/8 or 9/10 identities had an actuarial probability of survival of 92% (95 CI: 77-100%) and 77% (95% CI: 56-98%), respectively (P ¼ 0.3) (Figure 1d ). The use of PBSC, despite showing a clear impact on survival (80 vs 47%), did not reach statistical significance, probably due to the low number of patients receiving them.
In multivariate analysis (Table 3) , only donor age (P ¼ 0.003; RR ¼ 3.1 (95% CI: 1.3-7.1)) and donor-patient HLA-matching 8/8, 9/10 or 10/10 at allele level (P ¼ 0.009; RR: 7.7 (95% CI: 1.8-33)) maintained their significance. Among the subgroup of patients (n ¼ 11) receiving an UD-HCT from a donor younger than 36 years that matched for Impact of donor selection in unrelated HCT for CML E Carreras et al 8/8, 9/10 or 10/10 loci by HR techniques, the probability of survival was 91% (95% CI: 75-100%) at two years ( Figure 2 ). When univariate and multivariate analysis focused on the probability of DFS, the same risk factors were observed.
Risk assessment before UD-HCT When variables patient age, sex-mismatch and interval diagnosis-HCT were included in the EBMT prognostic score, we reproduced its predictive value (probability of survival by score: 1 ¼ 66%, 2 ¼ 50% and 3 ¼ 33%) (P ¼ 0.05) (Figure 3a) . When the two donor-related variables isolated in our multivariate analysis were included in the score (as: donor age p36 ¼ 0; donor age 436 ¼ 1; pairs with 8/8, 9/10 or 10/10 identities ¼ 0; remaining pairs ¼ 1), we improved notably the model identifying five subgroups of patients with a clearly different probability of survival (score 0-1 ¼ 100%; 2 ¼ 74%; 3 ¼ 55%; 4 ¼ 37%; 5 ¼ 0%) (Po0.0001) (Figure 3b ).
Discussion
The present study confirms the progressive improvement of UD-HCT outcome in patients with CML. When we compared the present results with those observed in our previous analysis, including a similar group of patients with CML undergoing UD-HCT between 1989 and 1998, the most remarkable aspect was the increase in survival. 8 Specifically, actuarial probability of survival in our initial series was 30% for patients in 1CP (40% for those undergoing HCT after 1995). In the present series, the probability of survival was 38% in the period 1994-1999, increasing to 61% in 1999-2003. This favourable evolution was attributable to the reduction of TRM. Cumulative incidence of TRM for UD-HCT performed since 1999 was 40%. This result compares favourably with the 57% observed in the period 1994À1999 and with the 77% in the previous series. As in our previous study, the probabilities of DFS and SRV were very similar, due to the low incidence of relapses (cumulative incidence of relapse 5%). The analysis of pretransplant variables with impact on survival also showed interesting differences when comparing this series with the previous study. When our first analysis was limited to patients in 1CP receiving UD-HCT between 1995 and 1998, the main risk factors in multivariate analysis were patient age, interval between diagnosis and UD-HCT and donor-recipient matching for HLA-A, -B by serological methods and DRB1 by DNA methods. In the present series, all these patient-related risk factors did not show any impact on survival, and only two donor-related risk factors had statistical significance: donor age and donor-recipient pairs matched at allele level for eight or more loci.
Despite the fact that patients younger than 25 years offered the best outcomes in the present series, patients' age disappeared as a risk factor in multivariate analysis. This fact is attributable to the notable improvement in survival among patients older than 30 years (51 vs 16% in patients of 30-39 years and 43 vs 0% in those older than 40 years when comparing the present with the previous series).
In univariate analysis, the use of an 'early' CsA schedule for GvHD prophylaxis showed a clear impact on survival among patients receiving CsA þ MTX (80 vs 39% when comparing CsA since day À7 with day À1; P ¼ 0.001); impact that disappeared in multivariate analysis, probably due to the relatively low number of patients. Nevertheless, we think that this strategy of prophylaxis described by the Genoa group should be kept in mind due to its simplicity and possible effectiveness. 15 Similarly, we could not reproduce the impact on survival of peripheral blood HCT that the Essen group described. 16 Despite showing a better survival rate, the low number of patients receiving this type of haematopoietic cells, and the fact that all of them received the transplant after 1999, with CsA since day À7, and from donors that matched using HR methods, precluded any valuable analysis in this subgroup.
The relationship between the degree of donor-recipient matching and survival has been reported by several large series. All studies performed in occidental countries demonstrated the impact of class I and class II mismatches, especially the DRB1, B and A loci. Furthermore, several recently published analyses have demonstrated the impact of C locus in results of UD-HCT and that, as a minimum, A, B, C and DRB1 loci must be considered in the unrelated donor search. [17] [18] [19] In our series, 8/8 HR pairs showed similar results to 9/10 HR pairs and poorer outcome than 10/10 pairs, probably due to nontested C or DQB1 mismatches. These results coincide with those offered recently by the NMDP and the Seattle team. The NMDP study showed that a single mismatch has an 8À12% of impacting survival and that mismatches at antigen level have a greater negative impact that allelic mismatches. 17 The Seattle analysis showed that a single allelic or antigenic mismatch have a special impact among CML-1CP patients. 19 The impact of a donor's age has also been observed in the large series published by the NMDP. 20 The exact reason for this phenomenon is not well known but could be attributed to the progressive allo-immunization throughout life, a fact that will progressively reduce tolerance to the recipient antigens. Owing to the usual close parallelism between donors' and patients' age in HCT performed between siblings, this effect had not been previously observed. Another donor-dependent variable with an impact on survival described by other authors could not be identified in our series probably due to the low number of patients included; namely, the impact of donor-recipient matching for CMV serological status. Impact of donor selection in unrelated HCT for CML E Carreras et al Surprisingly, despite the apparent absence of prognostic value of variables such as patient age, sex-match and interval diagnosis-HCT in uni-and multivariate analysis, when included in the risk assessment score described by Gratwohl et al., 14 they discriminated three subgroups of patients with different prognosis. Additionally, when adding the two donor-dependent variables, the prognostic score was even more predictive, showing five well-defined subgroups of patients with a clearly different probability of survival. This observation, if reproduced in largest series, could be very helpful to predict the outcome of CML-1CP patients receiving a UD-HCT.
In summary, our results show that when a patient with CML in 1CP receives a UD-HCT from a young and fully allele-matched donor (10/10 HR) the probability of survival is higher than 90%. Despite that, as management of chronic phase CML patients has changed dramatically since the imatinib introduction, at the present time it is difficult to establish the indication for UD-HCT, except for very young patients and for those that do not tolerate or do not respond to imatinib. In patients with poor prognosis, CML requiring a prompt UD-HCT, young donors with a single mismatch can also offer excellent results. Impact of donor selection in unrelated HCT for CML E Carreras et al
